COVID-19: Clinical aspects and therapeutics responses

doi:10.1016/j.jsps.2020.06.022

	COVID-19: Clinical aspects and therapeutics responses
	Khan, Suliman 1; Ali, Ashaq 2,3; Shi, Hongwei 4; Siddique, Rabeea 1; Shabana 2,3; Nabi, Ghulam 5; Hu, Junjie 6; Wang, Tiejun 7; Dong, Men 2,3; Zaman, Wajid 8; Han, Guang 9
	2020
发表期刊	SAUDI PHARMACEUTICAL JOURNAL
ISSN	1319-0164
卷号	28 期号:8 页码:1004-1008
摘要	COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retro-spective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recov-ery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
关键词	COVID-19 Therapeutics Mild symptoms TCM Recoveries
学科领域	Pharmacology & Pharmacy
DOI	10.1016/j.jsps.2020.06.022
收录类别	SCI
语种	英语
WOS关键词	CORONAVIRUS ; PNEUMONIA ; MEDICINE
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000557427600013
出版者	ELSEVIER
文献子类	Article
出版地	AMSTERDAM
EISSN	2213-7475
资助机构	Second Affiliated Hospital of Zhengzhou University, Zhengzhou China ; Chinese Postdoctoral Science FoundationChina Postdoctoral Science Foundation
作者邮箱	suliman.khan18@mails.ucas.ac.cn ; hg7913@hotmail.com
作品OA属性	Green Published, gold
引用统计	被引频次：37[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ibcas.ac.cn/handle/2S10CLM1/21637
专题	系统与进化植物学国家重点实验室
作者单位	1.Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China 2.Henan Med Key Lab Translat Cerebrovasc Dis, Zhengzhou, Peoples R China 3.Chinese Acad Sci, Wuhan Inst Virol, Xiao Hong Shan 44, Wuhan, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 5.Wuhan Univ, Sch Life Sci, Key State Lab Virol, Wuhan, Peoples R China 6.Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang 050024, Hebei, Peoples R China 7.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China 8.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Breast Surg, Wuhan, Peoples R China 9.Chinese Acad Sci, Inst Bot, State Key Lab Systemat & Evolutionary Bot, Beijing 100093, Peoples R China 10.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China
推荐引用方式 GB/T 7714	Khan, Suliman,Ali, Ashaq,Shi, Hongwei,et al. COVID-19: Clinical aspects and therapeutics responses[J]. SAUDI PHARMACEUTICAL JOURNAL,2020,28(8):1004-1008.
APA	Khan, Suliman.,Ali, Ashaq.,Shi, Hongwei.,Siddique, Rabeea.,Shabana.,...&Han, Guang.(2020).COVID-19: Clinical aspects and therapeutics responses.SAUDI PHARMACEUTICAL JOURNAL,28(8),1004-1008.
MLA	Khan, Suliman,et al."COVID-19: Clinical aspects and therapeutics responses".SAUDI PHARMACEUTICAL JOURNAL 28.8(2020):1004-1008.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
Khan-2020-COVID-19_ （545KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览请求全文